DOCTOR, MOST PEOPLE ASSOCIATE BREAST RECONSTRUCTION WITH THE SINGLE OR DOUBLE MASTECTOMY. BUT WHAT ABOUT A LUMPECTOMY, WHEN ONLY PART OF THE BREAST IS REMOVED? JOINING US LIVE THIS MORNING IS MERCY ...

Lumpectomy is the gold standard for breast cancer surgery, says Kirstyn E. Brownson, MD, a surgical breast oncologist at Huntsman Cancer Institute. We asked Dr. Brownson to explain what a lumpectomy ...

Many patients undergoing lumpectomy surgery at NYU Langone Medical Center for the removal of an early detected breast tumor - the surgical option of choice for this diagnosis -- are benefitting from ...

Breast cancer death rates have been declining since 1989, but the disease remains the second leading cause of cancer death in women. And incidence rates have increased slightly in recent years. For ...

For many years, lumpectomy has been the most common surgical procedure to treat breast cancer. In a 2014 study in the Journal of the American Medical Association, researchers examined medical records ...

The FDA approved pegulicianine (LumiSight) as an optical imaging agent for detecting residual cancer after breast-conserving surgery (BCS). The approval stipulates use of pegulicianine with the ...

As many as 40% of lumpectomies leave positive margins that necessitate a second surgery, but a novel fluorescent imaging agent used along with a direct visualization system may improve complete ...

THEN TO. IT’S IMPORTANT FOR US AS A WOMAN TO FEEL COMFORTABLE WITHIN HERSELF. WHEN ARVIN RAWLINGS WAS DIAGNOSED WITH BREAST CANCER AND FOUND OUT SHE NEEDED SURGERY, SHE WORRIED HOW IT WOULD MAKE HER ...

Lumpectomy procedures have become more refined in combination with chemotherapy and radiation, allowing women with breast cancer to conserve more of their breasts when undergoing treatment, according ...

NEWTON, Mass., Dec. 18, 2025 /PRNewswire/ -- Lumicell, Inc., a leader in developing innovative fluorescence-guided imaging technologies for cancer detection, today announced a new collaboration with ...

Approval was supported by data from a randomized, intra-patient controlled trial, which included patients with confirmed invasive breast cancer, ductal carcinoma in situ, or both. The Food and Drug ...

The MarketWatch News Department was not involved in the creation of this content. -- Independent investigators from the University of Pisa presented new data at the 2026 European Congress of Radiology ...